All
Dinutuximab Approved for High-Risk Neuroblastoma
March 10th 2015Dinutuximab (Unituxin) has been approved by the FDA in combination with interleukin-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), and isotretinoin as a frontline therapy for pediatric patients with high-risk neuroblastoma.
Rindopepimut Gains Breakthrough Designation for EGFRvIII-Positive Glioblastoma
February 23rd 2015The FDA has granted rindopepimut (Rintega) a Breakthrough Therapy Designation for the treatment of adult patients with glioblastoma multiforme (GBM) that test positive for the epidermal growth factor receptor (EGFR) variant (EGFRvIII).
Frontline Revlimid Approved for Multiple Myeloma
February 18th 2015Lenalidomide (Revlimid) plus dexamethasone has been approved by the FDA for the treatment of newly diagnosed patients with multiple myeloma who are not candidates for stem cell transplant, based on findings from the phase III FIRST trial.
Integrating Olaparib into Clinical Practice Represents Important Step for Oncologists, Patients
February 17th 2015To gain insight into the integration of olaparib (Lynparza) into clinical practice, Targeted Oncology interviewed Ursula A. Matulonis, MD, medical director of gynecologic oncology at Dana-Farber Cancer Institute.
Early Research Under Way to Improve Drug Delivery in Ovarian Cancer
February 10th 2015Targeted agents have become available in recent years to treat many major cancers, but for women with ovarian cancer, standard treatment following cytoreductive surgery remains systemic intravenous/intraperitoneal chemotherapy with a platinum agent and a taxane. Approximately 80% of women who receive first-line treatment with this platinum-based regimen experience relapsed disease. However, early research indicates that more and better options may be on the way.
Obinutuzumab iNHL Trial Ends Early, Genentech to File for FDA and EMA Approval
February 5th 2015Genentech, the manufacturer of obinutuzumab, plans to file for FDA and EMA approval after a phase III study of the anti-CD20 agent in indolent non-Hodgkin lymphoma (iNHL) garnered positive results in an interim analysis.